<DOC>
	<DOCNO>NCT02125578</DOCNO>
	<brief_summary>The primary objective identify high safe well-tolerated dose frequency BIIB017 ( PEGylated Interferon Beta-1a ) subcutaneous ( SC ) , within range 63 188 mcg , give every week every 4 week healthy volunteer ( HV ) .</brief_summary>
	<brief_title>A Multiple Dose Safety Study PEG-IFN Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Body Mass Index ( BMI ) 18 35 kg/m2 , inclusive , minimum body weight 50.0 kg screening . All male subject female subject childbearing potential must willing able practice effective birth control study willing able continue contraception 30 day last dose study treatment . Key Abnormal screen baseline blood urine test determine clinically significant Investigator . Hematologic hepatic enzyme laboratory value outside normal range . History severe allergic anaphylactic reaction . History clinicallysignificant ( determined Investigator ) cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal and/or major disease , and/or history seizure disorder . A family history MS firstdegree relative . A fever ( body temperature &gt; 38Â°C ) symptomatic viral bacterial infection ( include upper respiratory infection ) within 1 week prior Day 1 . Abnormal ECG value determine Investigator . Positive test result hepatitis C antibody , hepatitis B surface antigen ( HBsAg ) , human immunodeficiency virus ( HIV ) antibody . Female subject consider pregnancy , currently pregnant breastfeeding . Subjects receive tattoo body piercing ( include earring ) within 60 day baseline subject consider get tattoo body pierce ( include earring ) next 60 day . Use prescription nonprescription medication could inhibit bone marrow liver function . Any previous treatment interferon product . Participation investigational drug study within 4 week prior Day 1 within 5 halflives investigational treatment , whichever longer . Treatment Flu Vaccine within 1 week prior Day 1 . NOTE : Other protocoldefined inclusion/exclusion Criteria May Apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>